Clinical Trial Update: A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) [Phase 2]

View source ↗

Summary

A Phase II dose-ranging study (INDUS-3) of AUR101 in plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• AUR101

Snippet

Sponsor: Aurigene Discovery Technologies Limited | Conditions: Plaque Psoriasis | Phase 2 | Status: COMPLETED